IsoPET® Therapy | patient expression of interest

IsoPet® is now commercially available as part of a company-sponsored program to gain experience on the use of the product and to share the results of this therapy with the veterinary community. Interested pet owners should send this completed form to mkorenko@radiogel.com.

Vista Veterinary Hospital will review the information and provide their recommendation regarding applicability of IsoPet® therapy.

Pet Owner Details:

Pet Parent Name

Cell Phone Number

Address

CIty | State | Zip

Pet Details:

Pet Name

Pet Breed

Pet Age

Pet Approximate Weight

General Health

Health issues other than the tumor

Tumor Details:

Approximate Shape

Approximate Diameter

Tumor Location

Tumor Type (if known)

Slow or fast growing – e.g. Approximate length of time since first observed

Recurring tumor?

Previous Tumor Therapies (if selected, medical records will be requested).

I understand the above details and consent to be contacted to determine further eligibility

Please enter the code:

The Privacy Policy applies.

Note: Please fill out the fields marked with an asterisk.

General Understanding:

You will be participating in a developmental therapy. The therapy has demonstrated limited, but positive results. The data from the tests will be made available to Vivos Inc. and other clinics and could be included in published paper or conferences. Since it is developmental the pet owner recognizes there are risks.

IsoPET® therapy price is competitive with the cost of external beam therapy.

CURRENT RELEASE

Vivos Inc. STOCK SYMBOL REVERTS TO RDGL. UNIVERSITY OF MISSOURI REPORT NEAR COMPLETION

Richland WA, July 29, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK:RDGL), stock symbol reverts back to RDGL effective with the open of trading on Monday, July 29. As previously disclosed, the D at the end of the stock ticker is removed 20 business days following the completion of the reverse stock split that was completed on June 28, 2019.

Additionally, the University of Missouri is completing the final report on the IsoPet® therapy that was conducted over the last year. After receiving that report, we will submit it to the FDA and schedule a pre-submittal meeting to emphasize the key points of the completed test plan.

We are greatly encouraged that the tests demonstrate that IsoPet® was safe and effective. In particular, since the University of Missouri had both CT and PET, we were able to demonstrate the perfusion of IsoPet® into the tumor, which was one of the FDA's primary questions among others.

At this upcoming meeting we intend to refine the remaining testing needed to complete the pre-clinical requirements to write the Investigational Device Exemption, IDE. Obtaining IDE approval after submittal typically takes at least eight months.

Mike Korenko said "Our primary near-term emphasis it to expand our IsoPet® therapy commercially, while continuing to advance RadioGel™ within the FDA, with the goal of securing the IDE for human trials."

About Vivos Inc. (OTC:RDGL) >> Read Full Release

PRESS RELEASES

Click here for more news and updates

Stock Quote

Links

VIVOS Inc. (OTCMKTS: RDGL)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E: mkorenko@radiogel.com